Age-related macular degeneration (AMD) remains a leading cause of vision loss globally, with significant advancements in ...

This systematic review comprehensively summarizes treatment approaches for all types of age-related macular degeneration (AMD ...

A literature search identified 70 eyes with retinal vasculitis or vascular occlusion following brolucizumab for wet age-related macular degeneration. Twenty of 42 eyes experienced vision loss.

In a statement to Medscape Medical News, Apellis said the rate of retinal vasculitis in real-world use was about 0.01% per injection. "We are in the process of thoroughly investigating all cases ...

In a press release that coincided with Witkin's report, Apellis stated that there is "No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis ...

FORT LAUDERDALE, Fla. — Rare cases of occlusive retinal vasculitis have occurred with intravitreal therapies, and fluorescein angiography is an important tool to identify and diagnose the ...

Looking at adverse effects, intraocular inflammation occurred in 4% of patients with brolucizumab versus 2.9% with aflibercept, retinal vasculitis occurred in 0.9% and 0.6%, and retinal vascular ...

Fundus fluorescein angiography showed retinal vasculitis in both eyes (Figure 2a, b). The review of his medical history revealed that he had ankylosing spondylitis. Figure 1 ...

Apellis issued updated figures for the number of people who developed retinal vasculitis after receiving its eye medication Syfovre, estimating the rate at 0.01% per injection.

No cases of occlusive retinal vasculitis were reported. An FDA target action date of August 19, 2025 has been set for the application. References: ...